Quantcast

Latest Panitumumab Stories

2011-04-06 15:52:35

Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6. Patients with advanced colorectal cancer are typically treated with combination chemotherapy with fluorouracil or the derivative product, capecitabine with or without levofolinic acid with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) given alone,...

2011-03-30 15:05:00

THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC). Amgen believes that Vectibix in combination with chemotherapy provides an important...

2011-03-18 07:06:00

THOUSAND OAKS, Calif., March 18, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix(®) (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic...

2011-03-01 15:00:00

REDWOOD CITY, Calif., March 1, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced the publication of preclinical data demonstrating that its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations. This study was published in the March 1, 2011...

2010-12-02 07:00:00

BURLINGTON, Mass., Dec. 2, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the testing rate for epidermal growth factor receptor (EGFR) mutation--a predictor of response to Genentech/Roche/OSI/Chugai's EGFR inhibitor Tarceva--in non-small-cell lung cancer (NSCLC) patients will increase by approximately 50 percent over the next 12 months, according to surveyed U.S. oncologists. In line with...

2010-10-27 02:21:47

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA. "Recent retrospective correlative analyses of...

2010-10-12 16:42:21

Adding the targeted drug cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer does not improve response rate, progression-free survival or overall survival, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. Professor Kjell Magne Tveit from Oslo University Hospital, Norway, reported the unexpected results from the NORDIC VII study, which included 566 patients from Sweden, Denmark,...

2010-10-05 15:57:00

THOUSAND OAKS, Calif., Oct. 5 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy. "Cancer is a complex disease which requires innovative therapeutic approaches. Amgen is exploring numerous biologic pathways to develop novel therapies to treat cancer and lessen the side effects of cancer...

2010-10-04 16:05:00

THOUSAND OAKS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology. "Both studies demonstrated that Vectibix administered with chemotherapy...

2010-08-19 08:36:00

ROME, August 19, 2010 /PRNewswire/ -- Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) and published in the British Journal of...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related